Eletriptan

Drug #1706

Eletriptan is a selective serotonin (5HT-1) agonist. Eletriptan is given orally in the treatment of acute migraine attacks. It may be used during the established headache phase of an attack and is the preferred treatment in those who fail to respond to conventiaonal analgesics.

← Previous drug Next drug →

Primary Characteristics

It is of Synthetic origin and belongs to Triptamines and derivatives.

Molecular Weight: 382.52 · Non-proprietary name: Eletriptan.

Pharmacokinetics

Absorption: Eletriptan has an oral bioavailability is 25% (±25%).

Distribution: Eletriptan has a volume of distribution is 138 L. plasma protein binding is Moderate,Approx 85%.

Elimination: plasma half-life is 4hr.

Indications

Eletriptan is primarily indicated in conditions like Long-term treatment of reflux oesophagitis, Treatment of acute migraine attacks.

Contraindications

Eletriptan is contraindicated in conditions like Peripheral vascular disease, Uncontrolled hypertension, Severe hypertension associated with renal disease, Chronic intractable hypoglycaemia.

Dosage

Eletriptan's dosage details are as follows:

Dose	Single Dose	Frequency	Route	Instructions
Adult Dosage
30 mg	30 mg	Every 24h	PO	For migrain: The maximum daily dose should not exceed 80 mg.
Paediatric Dosage (20kg)
No data.
Neonatal Dosage (3kg)
No data.

Drug Interactions

4 interactions

Always consult your physician for the change of dose regimen or an alternative drug of choice that may strictly be required.

Side Effects

Eletriptan is known to cause more or less tolerable side effects which are usually transient. These include Abdominal pain, Agitation , Anorexia , Arthralgia, Asthenia , Ataxia, Bradycardia , Chest pain, Confusion, Depression, Drowsiness, Dry mouth, dyspepsia, Dyspnea, Edema, Euphoria, Glossitis, Hallucination , Hypotension , Increased urinary frequency, Insomnia, Muscle pain, Myalgia, Nausea, Pharyngitis, Pruritus , Restlessness, Rhinitis , Tinnitus, Transient increase in blood pressure, Tremor, Wheezing .

Warnings / Precautions

5HT1 agonists (e.g Eletriptan) should be used with caution in conditions which predispose to coronary artery disease (pre-existing cardiac disease), pregnancy and breast-feeding. 5HT1 agonists are recommended as monotherapy and should not be taken concurrently with other acute migraine therapies. Little information is available on the use of these drugs in the elderly (over 65 year). Caution is also required in mild or moderate hepatic impairment and renal impairment; not to be taken until 24 hours after stopping ergotamine-type prepration (ergotamine-type prepration not to be taken until 6 hours after Eletriptan)

Interference in Pathology

Eletriptan may interfere in the diagnosis of None well documented.

Available Brands

Click on a strength to view available brands.

Single Ingredient

Tabs

20 mg 40 mg

Storage Conditions

Eletriptan should be stored .

Drug Classification

1.7.1 — Acute migraine attack

Manufacturers

Manufacturers of Eletriptan in Pakistan:

Wilshire